Literature DB >> 16699369

Enhanced immunity to breast cancer in mice immunized with fibroblasts transfected with a complementary DNA expression library from breast cancer cells: Enrichment of the vaccine for immunotherapeutic cells.

Tae Sung Kim1, Amla Chopra, In Sug O-Sullivan, Edward P Cohen.   

Abstract

Breast cancer cells express an array of weakly immunogenic tumor-associated antigens (TAAs). Under appropriate circumstances, immunity to breast cancer can be induced, with potential benefits for patients with the disease. Here, we report a new cell-based vaccination strategy resulting in enhanced immunity to breast cancer in tumor-bearing mice. The strategy was designed to enrich the vaccine for highly immunogenic cells. The vaccine was prepared by transfer of unfractionated complementary DNA (cDNA) derived from a highly malignant breast neoplasm that arose spontaneously in a C3H/He mouse (SB5b) into an immunogenic fibroblast cell line. As the transferred cDNA spontaneously integrates into the genome of the recipient cells and is replicated as the cells divide, sufficient DNA to prepare the vaccine could be obtained from as few as 10(7) cells (4-mm tumor). Because only a small proportion of the transfected cell population was expected to have incorporated genes responsible for inducing immunity to the breast cancer, we devised a novel approach designed to enrich the transfected cell population for cells that induced immunity to the neoplasm. Aliquots of the transfected population were divided into small pools (initial inoculum = 4 x 10). Afterward, the cell number from each pool was allowed to expand in vitro. Pools containing greater numbers of immunogenic cells (identified by 2 independent assays) were subdivided for additional rounds of immune selection. Enhanced immunity to the neoplasm was detected in tumor-bearing mice treated solely by immunization with the enriched cell population. The immunity, mediated by CD8+ T cells, was sufficient to prolong the survival of mice with established breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699369     DOI: 10.1097/01.cji.0000197097.46100.bb

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  4 in total

1.  Melanoma vaccines: clinical status and immune endpoints.

Authors:  Deena M Maurer; Lisa H Butterfield; Lazar Vujanovic
Journal:  Melanoma Res       Date:  2019-04       Impact factor: 3.599

Review 2.  Enhancing cellular cancer vaccines.

Authors:  Edward P Cohen; Amla Chopra; InSug O-Sullivan; Tae Sung Kim
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

Review 3.  Cancer vaccines.

Authors:  Lisa H Butterfield
Journal:  BMJ       Date:  2015-04-22

Review 4.  The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy.

Authors:  Zhixiao Fang; Chunjie Jiang; Shengli Li
Journal:  Front Immunol       Date:  2021-02-03       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.